Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Ustekinumab for Type 1 Diabetes
Recruiting0 awardsPhase 2 & 3
Vancouver, British Columbia
This trial will assess if Ustekinumab can decrease C-peptide decline in participants with recent onset type 1 diabetes, in order to see if the drug is effective in protecting insulin-producing cells.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.